Seegnal Inc. Announces Q3 Filing Exemption and Appointment of a Special Committee to Review Strategic Alternatives

PR Newswire
Today at 6:10pm UTC

Seegnal Inc. Announces Q3 Filing Exemption and Appointment of a Special Committee to Review Strategic Alternatives

Canada NewsWire

CALGARY, AB, Nov. 20, 2026 /CNW/ -- Seegnal Inc. (TSXV: SEGN) (FSE: 2I1) ("Seegnal" or the "Company"), a developer of innovative healthcare technology focused on mitigating medication risks, announces the adoption of semi-annual financial reporting. This news release is being filed pursuant to Coordinated Blanket Order 51 – 933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933").

CBO 51-933 allows eligible venture issuers to voluntarily move from a quarterly to a semi-annual financial reporting framework. Seegnal's fiscal year ends on December 31. Under the provisions of CBO 51-933, Seegnal will be exempt from the requirements to file its nine-month interim financial statements and associated management's discussion and analysis ("MD&A") as it meets the eligibility criteria under CBO 51-933, which include being a venture issuer with annual revenues of less than $10 million and maintaining a clean 12-month continuous disclosure record. Accordingly, Seegnal will not be filing its interim financial statements for the nine-month period ending September 30, 2026 and associated MD&A.

Seegnal will continue to file audited annual financial statements (due within 120 days of December 31, 2026) and six-month interim financial reports (due next within 60 days of June 30, 2027). Seegnal remains committed to timely disclosure and will continue to report all material changes and significant developments as required under National Instrument 51-102 – Continuous Disclosure Obligations.

Special Committee

The Company's board of directors (the "Board") has established a special committee of independent directors (the "Special Committee") to lead the Company's evaluation of strategic and financing alternatives.

The Special Committee is exploring a full range of options, which may include, but are not limited to, a merger, sale, related party transaction or other alternative. To assist in its work, the Special Committee may engage professional advisors as it considers appropriate, including legal, financial and accounting advisors.

The Board has not set a timetable for this evaluation process, nor has it made any decisions regarding any potential strategic transaction. There can be no assurance that this process will result in any transaction. The Company does not intend to provide updates or make further comments regarding these matters unless and until it determines that additional disclosure is appropriate or required by law. Seegnal cautions that there are no guarantees that the evaluation processes will result in any particular outcome. The Company will continue to operate its business as usual as it undertakes these evaluation processes.

About Seegnal

Seegnal Inc. (TSXV: SEGN) (FSE: 2I1) is an innovative healthcare technology company dedicated to reducing medication-related harm where care begins. The Company's SaaS-based clinical decision support platform is designed to help clinicians prescribe with greater precision by integrating patient-specific data at the point of care, including medications, laboratory results, renal function, allergies, age and other relevant risk factors. By delivering more targeted, context-aware medication insights within existing clinical workflows, Seegnal aims to reduce alert fatigue, support safer prescribing and advance a more personalized standard of patient care. Seegnal's technology is deployed across healthcare settings and is used by approximately 15,000 clinicians in daily practice. For additional Company information, please visit https://www.seegnal.com/ and follow us on LinkedIn.

Forward-Looking Statements

This press release contains "forward-looking information" or "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities legislation. All statements included herein, other than statements of historical fact, including statements included in the "About Seegnal" section of this press release, are forward-looking statements. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. 

More particularly, and without limitation, this press release contains forward-looking statements with respect to: the statements in respect of the strategic review process and results thereof; the availability of strategic and financial alternatives; the ability of the Company to accomplish its business objectives and future plans; the likelihood of the Company or the Special Committee developing a feasible strategic and financial plan; and the success of any evaluations made by the Company, the Board and the Special Committee. Seegnal cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of Seegnal, including: expectations and assumptions concerning Seegnal and its products; the Special Committee's recommendations may not be feasible or provide positive results; the Company may require additional financing or other strategic or operational alternatives, which may not be available on acceptable terms or at all; and liquidity constraints may adversely affect the Company's ability to continue its operations, support its customers and meet its obligations, as well as other risks and uncertainties, including those described in Seegnal's filings available on SEDAR+ at www.sedarplus.ca.

The reader is cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of Seegnal. The reader is cautioned not to place undue reliance on any forward-looking statements. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

The forward-looking statements contained in this press release are made as of the date of this press release, and Seegnal does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Seegnal Inc.